MabTics

Executive Summary

MabTics is a preclinical-stage biotechnology company based in Seoul, South Korea, focused on developing monoclonal antibody therapeutics for oncology and autoimmune diseases. Founded in 2018, the company has raised $1.6 million to advance its pipeline of antibody candidates targeting cancer and immune-mediated disorders. MabTics operates in the competitive antibody therapeutics space, leveraging proprietary engineering platforms to generate optimized antibodies with improved efficacy and safety profiles. As a private, early-stage entity with 10-50 employees, the company is still in the discovery and preclinical validation phase, with no disclosed lead candidates or clinical data. The limited funding and early stage indicate significant development risk, though the focus on high-value therapeutic areas provides potential upside. Key near-term value drivers include selection of development candidates, progression toward IND-enabling studies, and potential partnership or licensing opportunities.

Upcoming Catalysts (preview)

• Q1 2026Lead candidate nomination and in vivo proof-of-concept data50% success
• Q4 2026IND-enabling studies initiation30% success
• TBDStrategic partnership or licensing deal20% success